TPP Global Development Ltd Enters Into a Collaboration Agreement With Sprint Biosciences AB to Develop Small Molecule Inhibitors of Choline Kinase
EDINBURGH, Scotland--(BUSINESS WIRE)--TPP Global Development Ltd (TPP) enters into a collaboration with Sprint Bioscience AB to develop small molecule inhibitors of choline kinase as human therapeutics for the treatment of cancer.
Under the terms of the agreement TPP and Sprint Bioscience will work together to further the development of small molecule inhibitors of choline kinase as human therapeutics for the treatment of cancer. Tom Brown, TPP’s CEO commented, “We are delighted to have entered into this agreement to work with Sprint Bioscience, and look forward to utilising their expertise in fragment-based drug discovery and development. Choline Kinase is an exciting metabolic target and fits well within the rest of TPP’s cancer metabolism portfolio.
Under the terms of the agreement TPP and Sprint Bioscience will work together to further the development of small molecule inhibitors of choline kinase as human therapeutics for the treatment of cancer. Tom Brown, TPP’s CEO commented, “We are delighted to have entered into this agreement to work with Sprint Bioscience, and look forward to utilising their expertise in fragment-based drug discovery and development. Choline Kinase is an exciting metabolic target and fits well within the rest of TPP’s cancer metabolism portfolio.